Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-02 |
2024-03 |
-0.31 |
-0.42 |
-0.11 |
-35.48% |
2024-03-06 |
2023-12 |
-0.39 |
-0.2 |
0.19 |
48.72% |
2023-11-07 |
2023-09 |
-0.55 |
-0.41 |
0.14 |
25.45% |
2023-08-10 |
2023-06 |
-0.51 |
-0.76 |
-0.25 |
-49.02% |
2023-05-08 |
2023-03 |
-0.64 |
-0.37 |
0.27 |
42.19% |
2023-03-07 |
2022-12 |
4.62 |
4.65 |
0.03 |
0.65% |
Date |
Firm |
Action |
From |
To |
2023-08-14 |
HC Wainwright & Co. |
Upgrade |
Neutral |
Neutral |
2023-06-05 |
HC Wainwright & Co. |
Upgrade |
Neutral |
Neutral |
2023-05-17 |
Citigroup |
Upgrade |
|
Buy |
2023-05-08 |
Stifel |
Upgrade |
|
Buy |
2023-03-30 |
JP Morgan |
Upgrade |
|
Neutral |
2023-03-20 |
HC Wainwright & Co. |
Upgrade |
|
Neutral |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-07 |
ASTLE CHRISTOPHER |
Chief Financial Officer |
6.50K |
Sale |
2023-06-15 |
ECOR1 CAPITAL, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2024-01-07 |
GALBRAITH KENNETH HARRY |
Chief Executive Officer |
23.76K |
Sale |
2022-11-09 |
JOSEPHSON NEIL M.D. |
Officer |
14.45K |
Sale |
2023-03-09 |
KLOMPAS NEIL A |
President |
17.73K |
Sale |
2024-01-07 |
MOORE PAUL ANDREW |
Officer |
7.37K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
EcoR1 Capital, LLC |
13.44M |
116.10M |
21.33% |
2023-06-29 |
BVF Inc. |
5.87M |
50.72M |
9.32% |
2023-06-29 |
Redmile Group, LLC |
5.66M |
48.91M |
8.99% |
2023-06-29 |
Morgan Stanley |
5.49M |
47.40M |
8.71% |
2023-06-29 |
Blackrock Inc. |
3.54M |
30.61M |
5.62% |
2023-06-29 |
Credit Suisse Ag/ |
2.51M |
21.68M |
3.98% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.91M |
16.51M |
3.03% |
2023-08-30 |
iShares Russell 2000 ETF |
1.21M |
8.79M |
1.93% |
2023-08-30 |
iShares Russell 2000 Value ETF |
487.76K |
3.53M |
0.77% |
2023-07-30 |
Fidelity Small Cap Index Fund |
481.57K |
3.59M |
0.76% |
2023-08-30 |
iShares NASDAQ Biotechnology ETF |
416.00K |
3.01M |
0.66% |
2023-06-29 |
Bridgeway Fds Inc-Omni Small Cap Value Fund |
336.90K |
2.91M |
0.53% |